title: Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog.
abstract: Sertoli-Leydig cell tumors are rare ovarian neoplasms. We report two unusual cases with bilateral SLCTs suggesting evidence of genetic predisposition and at high risk of recurrence. To reduce this risk, we exploited the use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for recurrence. Both patients remain in complete remission at >2 years after completing leuprorelin therapy. Of note, both patients carry DICER1 mutations, frequently found in pleuropulmonary blastoma syndrome.
authors.affiliation: The Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK.
authors.forename: Harsha Prasada
authors.initials: HP
authors.lastname: Lashkari
authors.forename: Ruth
authors.initials: R
authors.lastname: Nash
authors.forename: Assunta
authors.initials: A
authors.lastname: Albanese
authors.forename: Bruce
authors.initials: B
authors.lastname: Okoye
authors.forename: Robert
authors.initials: R
authors.lastname: Millar
authors.forename: Kathy
authors.initials: K
authors.lastname: Pritchard-Jones
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002648:Child; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018310:Sertoli-Leydig Cell Tumor / Q000188:drug therapy* / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide